Alnylam stock: TTR growth is strong, but the launch reset matters
ALNY stock analysis and fair value · bull and bear case
The call: SageNoodle rates Alnylam Pharmaceuticals Fairly Valued: base-case fair value USD 247 against a price of USD 231, 7% above the quote. Alnylam’s documented business update is a guidance reduction, not a collapse in current demand: Q2 TTR revenue grew 89% year over year, but management says early second-line launch demand was unusually strong and has normalized.
Alnylam stock is down 2.9% at $246.74, but the reason for today’s attention is unconfirmed. The latest documented catalyst is a lower TTR sales outlook despite rapid quarterly growth.
Valuation as of 1 Oct 2026 · Quote currency: USD. Latest quote: Fri, 09 Oct 2026 19:14:53 GMT.
Written with AI from the linked sources and reviewed by a SageNoodle editor. How we work.
Latest quote
USD 231.21
At publication
USD 246.74
Fair value
USD 246.74
Upside
+6.7%
P/E at publication
74.3x
EV/EBITDA
Not available
FCF yield
2.7%
ROIC Not available · Horizon Long term; preliminary estimate pending additional forward financial evidence
Why Alnylam Pharmaceuticals (ALNY) stock is mispriced
- 01
Alnylam’s documented business update is a guidance reduction, not a collapse in current demand: Q2 TTR revenue grew 89% year over year, but management says early second-line launch demand was unusually strong and has normalized.
- 02
That reset matters because the TTR franchise is the main growth engine: the lower annual outlook trims expected product revenue while the company continues to spend on launch and clinical programs.
- 03
At $246.74, the shares are fairly valued on this preliminary, scenario-based estimate; the case depends on sustained commercial growth and pipeline progress, neither of which today’s attention count establishes.
What Alnylam Pharmaceuticals does and how it makes money
Alnylam Pharmaceuticals (ALNY) is a Cambridge, Massachusetts biotechnology company that develops RNA interference (RNAi) medicines: therapies designed to silence messenger RNA and reduce production of targeted proteins. Its commercial business includes AMVUTTRA and ONPATTRO for transthyretin amyloidosis, and GIVLAARI and OXLUMO for rare diseases; it also earns collaboration and royalty revenue. Alnylam reported one operating segment in its second-quarter filing. Its latest results show how central the TTR franchise has become: AMVUTTRA and ONPATTRO generated $1.03 billion of Q2 2026 net product revenue, while the two rare-disease products contributed $141.9 million. The company’s revenue also includes collaboration and royalty streams, so product sales are not the whole income statement. Q2 2026 earnings release Q2 2026 Form 10-Q
For the financial history and all coverage, see ALNYLAM PHARMACEUTICALS, INC. (ALNY) company research.
The latest documented change is a lower TTR sales outlook
The quote puts ALNY at $246.74, down 2.9% today. That is the observed move, not an explanation for it: the five Reddit mentions and one fresh headline indicate attention, but do not establish what caused the decline. Q2 2026 earnings release
The quarter itself was not a sales contraction. TTR products brought in $1.03 billion, up 89% from Q2 2025; total product revenue was $1.172 billion, up 74%. AMVUTTRA contributed $1.012 billion, while ONPATTRO contributed $18 million. The tension is between fast reported growth and a less generous view of what that growth will look like across the full year.
Why did management reduce guidance after a strong quarter?
Alnylam says the U.S. second-line market for AMVUTTRA grew unusually quickly early in its launch because some patients progressing on stabilizers had been waiting for a new option. It now views that pent-up demand as satisfied and early-2026 second-line growth as normalized. That is a change in the expected pace of adoption, not an announcement that the medicine has lost approval or that the launch has stopped. Q2 2026 earnings release
Management’s sequential detail offers an important counterweight: U.S. TTR revenue rose $106 million from Q1, with a reported $129 million demand increase partly offset by approximately $20 million of inventory impact and a modest net-price reduction. International TTR revenue rose $14 million sequentially, primarily on increased demand in both hATTR-PN and ATTR-CM. The demand figures are company-reported; they do not erase the lower full-year outlook, but they make a simple “growth has stopped” interpretation too blunt.
The economics still deserve scrutiny. Cost of goods sold rose to 25.4% of net product revenue in Q2 2026 from 21.1% a year earlier; Alnylam attributed the increase primarily to higher AMVUTTRA sales and a higher blended royalty rate payable on those sales. Meanwhile, GAAP R&D expense rose 28% year over year and SG&A rose 8%, with the company pointing to clinical-trial spending and launch marketing. More sales are arriving, but they do not all fall through to operating profit.
What does the reset mean for ALNY valuation?
At $246.74, ALNY’s supplied metrics imply a 74.3x trailing P/E and a 2.7% trailing free-cash-flow yield. Those are demanding measures for a business whose annual TTR growth outlook has just been reduced, even though Q2 revenue expanded quickly. The company reported Q2 GAAP net income of $164.5 million and operating income of $231.4 million; a single profitable quarter is evidence of progress, not proof that earnings have settled into a stable run rate. Q2 2026 earnings release
There is no prior SageNoodle fair value to carry forward. Our preliminary scenario valuation uses direct equity values divided by an assumed 138.281 million diluted shares, matching the diluted weighted-average share count reported for Q2 2026. It assigns $29.0 billion, $34.1 billion and $39.4 billion of equity value to bear, base and bull cases, respectively, or about $210, $247 and $285 per share. The scenario values are analyst assumptions, not company guidance; the base case rounds to the $246.74 share price. That supports a preliminary “fairly valued” view, with a wide range because the central commercial question—how durable normalized AMVUTTRA demand will be—remains unresolved. Q2 2026 earnings release
The long-term case is intact, but less automatic
The guidance reduction changes the near-term growth bar; it does not, by itself, invalidate the broader thesis that Alnylam can turn RNAi medicines into a growing commercial business. The release describes ongoing international expansion, including a BeOne Medicines distribution agreement for mainland China and Macao, subject to marketing authorization, and reports continued progress across clinical programs. But pipeline candidates are not present revenue, and the China arrangement is conditional rather than a booked sales stream. Q2 2026 earnings release
The cleanest near-term test is whether demand supports the revised sales range without sacrificing price or requiring still heavier commercial spending. Alnylam has said it expects initial Phase 1 ALN-HTT02 results in Huntington’s disease at the EHDN Clinical Research Congress on October 23, 2026. That is a pipeline event, not a substitute for evidence that AMVUTTRA’s normalized demand can sustain the valuation. Q2 2026 earnings release
Follow SageNoodle on Google
Alnylam Pharmaceuticals revenue, margins and cash flow
Revenue (USD, billions)
Margins (%)
Free cash flow (USD, billions)
Estimated ROIC (%)
Net debt (USD, billions)
Monetary values are in USD; revenue, FCF and net debt are in billions; EPS is per share. Missing values appear as gaps and “Not available.” Source: SEC EDGAR XBRL filings, latest restated values; quarterly cash flow derived from year-to-date figures; Q4 = fiscal year minus nine months. ROIC is NOPAT (21% tax) over debt plus equity.
| Period | Revenue | Gross % | Op % | FCF | EPS | ROIC % | Net debt |
|---|---|---|---|---|---|---|---|
| FY2016 | 0.05 | Not available | -900.3 | -0.37 | Not available | Not available | Not available |
| FY2017 | 0.09 | Not available | -556.2 | -0.49 | Not available | Not available | Not available |
| FY2018 | 0.07 | Not available | -1087.6 | -0.69 | Not available | Not available | Not available |
| FY2019 | 0.22 | Not available | -427.5 | -0.42 | -8.11 | Not available | Not available |
| FY2020 | 0.49 | Not available | -168.1 | -0.69 | -7.46 | -54.2 | -0.31 |
| FY2021 | 0.84 | Not available | -83.9 | -0.72 | -7.20 | -44.3 | -0.14 |
| FY2022 | 1.04 | Not available | -75.7 | -0.61 | -9.30 | Not available | Not available |
| FY2023 | 1.83 | Not available | -15.4 | 0.04 | -3.52 | Not available | Not available |
| FY2024 | 2.25 | Not available | -7.87 | -0.04 | -2.18 | Not available | Not available |
| FY2025 | 3.71 | Not available | 13.5 | 0.47 | 2.33 | Not available | Not available |
What Alnylam Pharmaceuticals management has said
Demand
Paraphrased commentary
Management attributed the revised outlook to early-2026 normalization in second-line AMVUTTRA demand after launch-period pent-up demand.
Guidance
Direct quote
“we remain confident in the trajectory of our ongoing ATTR-CM launch”
Alnylam Pharmaceuticals fair value: bear, base and bull scenarios
Dot marks the latest quote of USD 231.21.
Bear
25%USD 210
Direct equity valuation using assumed equity value divided by diluted shares.
Equity value USD 29.00B ÷ 0.138B diluted shares
- Equity value
- $29.0 billion; analyst scenario assumption
- Diluted shares
- 138.281 million, Q2 2026 diluted weighted-average shares
- Calculation
- $29.0 billion / 0.138281 billion shares = $209.72 per share, rounded to $209.8
This case assumes normalized second-line demand grows too slowly to support the revised outlook over time and that launch costs and product royalties continue to limit operating leverage.
Base
50%USD 247
Direct equity valuation using assumed equity value divided by diluted shares.
Equity value USD 34.10B ÷ 0.138B diluted shares
- Equity value
- $34.1 billion; analyst scenario assumption, approximately the supplied market capitalization
- Diluted shares
- 138.281 million, Q2 2026 diluted weighted-average shares
- Calculation
- $34.1 billion / 0.138281 billion shares = $246.60 per share; fair value rounded to $246.74
This case assumes the revised commercial outlook is achievable, TTR demand continues to expand at a more normalized pace, and pipeline potential offsets rather than immediately replaces the franchise’s growth contribution.
Bull
25%USD 285
Direct equity valuation using assumed equity value divided by diluted shares.
Equity value USD 39.40B ÷ 0.138B diluted shares
- Equity value
- $39.4 billion; analyst scenario assumption
- Diluted shares
- 138.281 million, Q2 2026 diluted weighted-average shares
- Calculation
- $39.4 billion / 0.138281 billion shares = $284.92 per share, rounded to $284.9
This case assumes sustained AMVUTTRA demand, wider international contribution, and pipeline advancement support stronger long-run revenue and earnings capacity than the current price implies.
Alnylam Pharmaceuticals (ALNY) stock: bullish vs bearish case
Bull case
- Q2 TTR product revenue grew 89% year over year, with reported U.S. and international sequential demand gains.
- AMVUTTRA’s commercial expansion is supported by ongoing international launches and a China distribution agreement conditional on marketing authorization.
- The company reported positive GAAP operating income and net income in Q2 2026 while continuing to advance clinical programs.
Bear case
- The TTR sales guidance reduction shows that early launch uptake did not translate into the same expected pace of second-line demand.
- AMVUTTRA’s higher blended royalty burden contributed to cost of goods sold rising as a share of product revenue.
- The stock’s 74.3x trailing P/E and 2.7% FCF yield leave valuation sensitive to any further slowdown in growth or weaker-than-expected operating leverage.
Alnylam Pharmaceuticals stock risks
| Risk | Severity | Probability | Rationale |
|---|---|---|---|
| AMVUTTRA demand normalization | High | Medium | The company lowered TTR guidance after concluding that early second-line launch growth included pent-up demand. A weaker-than-expected normalized trajectory would pressure the main growth engine. |
| Commercial margin pressure | Medium | Medium | Q2 cost of goods sold increased as a proportion of net product revenue, which Alnylam attributed primarily to a higher blended royalty rate on AMVUTTRA sales. Launch marketing also remains an investment. |
| Clinical and regulatory execution | High | Medium | Pipeline candidates and expanded indications remain subject to clinical results and regulatory review; the release explicitly warns that investigational programs may not succeed or gain approval. |
Alnylam Pharmaceuticals catalysts: what could move ALNY stock
- 2026-10-23Neutral
ALN-HTT02 Phase 1 results presentation
Alnylam said it plans to present initial results in patients with Huntington’s disease at the EHDN Clinical Research Congress.
- Not specifiedNeutral
Next reported commercial update
Alnylam Pharmaceuticals fair value history
| Period | Fair value | Verdict | Note |
|---|
Alnylam Pharmaceuticals news
Alnylam Pharmaceuticals stock: common questions
- Is Alnylam Pharmaceuticals (ALNY) stock undervalued or overvalued?
- SageNoodle rates Alnylam Pharmaceuticals Fairly Valued: base-case fair value USD 247 against a price of USD 231, 7% above the quote. Alnylam’s documented business update is a guidance reduction, not a collapse in current demand: Q2 TTR revenue grew 89% year over year, but management says early second-line launch demand was unusually strong and has normalized.
- What is Alnylam Pharmaceuticals's fair value?
- Bear USD 210 (25% probability, Direct equity valuation using assumed equity value divided by diluted shares.); Base USD 247 (50% probability, Direct equity valuation using assumed equity value divided by diluted shares.); Bull USD 285 (25% probability, Direct equity valuation using assumed equity value divided by diluted shares.). This case assumes the revised commercial outlook is achievable, TTR demand continues to expand at a more normalized pace, and pipeline potential offsets rather than immediately replaces the franchise’s growth contribution.
- What is the bull case for ALNY stock?
- Q2 TTR product revenue grew 89% year over year, with reported U.S. and international sequential demand gains. AMVUTTRA’s commercial expansion is supported by ongoing international launches and a China distribution agreement conditional on marketing authorization. The company reported positive GAAP operating income and net income in Q2 2026 while continuing to advance clinical programs.
- What is the bear case for ALNY stock?
- The TTR sales guidance reduction shows that early launch uptake did not translate into the same expected pace of second-line demand. AMVUTTRA’s higher blended royalty burden contributed to cost of goods sold rising as a share of product revenue. The stock’s 74.3x trailing P/E and 2.7% FCF yield leave valuation sensitive to any further slowdown in growth or weaker-than-expected operating leverage.
- What are the biggest risks to Alnylam Pharmaceuticals stock?
- AMVUTTRA demand normalization (High severity): The company lowered TTR guidance after concluding that early second-line launch growth included pent-up demand. A weaker-than-expected normalized trajectory would pressure the main growth engine. Commercial margin pressure (Medium severity): Q2 cost of goods sold increased as a proportion of net product revenue, which Alnylam attributed primarily to a higher blended royalty rate on AMVUTTRA sales. Launch marketing also remains an investment. Clinical and regulatory execution (High severity): Pipeline candidates and expanded indications remain subject to clinical results and regulatory review; the release explicitly warns that investigational programs may not succeed or gain approval.
- What could move ALNY stock next?
- 2026-10-23: ALN-HTT02 Phase 1 results presentation. Alnylam said it plans to present initial results in patients with Huntington’s disease at the EHDN Clinical Research Congress. Not specified: Next reported commercial update.
Company reference pages
Browse company filings and market quotes to check the latest information. These pages update over time and are separate from the documents cited in this report.